Wugen Presents New Preclinical Data Supporting the Safety and Efficacy of WU-CART-007 for T-Cell Malignancies at the 63rd Annual Society of Hematology (ASH) Annual Meeting

ST. LOUIS & SAN DIEGO–(BUSINESS WIRE)–Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today presented new preclinical data supporting the safety and efficacy profile of WU-CART-007 for T-cell malignancies. Further, today’s data highlighted Wugen’s clinical readiness and robust manufacturing process for WU-CART-007. The U.S. Food and Drug Administration (FDA) has clea
Click here to view original post